drugset / Trial / NCT06578676

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

NCT06578676

RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.

Timeline

Start
2024-06-20
Primary completion
2024-09-02
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg Oral
Subject Ezetimibe Unknown 10 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral